# Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

> **NCT00732745** · PHASE1 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Adenocarcinoma of the Gastroesophageal Junction
- Esophageal Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** oxaliplatin
- **DRUG:** vandetanib
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00732745
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Lost funding for Phase II portion of study
- **Last updated:** 2011-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00732745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00732745, "Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00732745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*